Details of the Drug

General Information of Drug (ID: DMKMJHE)

Drug Name

Cemiplimab

Synonyms

REGN2810; REGN-2810; REGN 2810

Indication

Disease Entry	ICD 11	Status	REF
Cutaneous squamous cell carcinoma	2C30	Approved	[1]
------------------------------------------------------------------------------------

Affected Organisms

Humans and other mammals

ATC Code

L01FF06: Cemiplimab

L01FF: PD-1/PDL-1 (Programmed cell death protein 1/death ligand 1) inhibitors

L01F: MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES

L01: ANTINEOPLASTIC AGENTS

L: ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS

Drug Type

Monoclonal antibody

ADMET Property

Absorption Cmax: The maximum plasma concentration (Cmax) of drug is 166 mg/L []
Clearance: The clearance of drug is 0.32 L/day []
Half-life: The concentration or amount of drug in body reduced by one-half in 19 days []
Vd: The volume of distribution (Vd) of drug is 5.3 L []

Cross-matching ID

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Programmed cell death protein 1 (PD-1)	TTNBFWK	PDCD1_HUMAN	Modulator	[1]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease

Cutaneous squamous cell carcinoma

ICD Disease Classification

2C30

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Programmed cell death protein 1 (PD-1)	DTT	PDCD1	7.26E-01	-0.01	-0.03

Molecular Expression Atlas (MEA)

Jump to Detail Molecular Expression Atlas of This Drug

References

1	2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.